{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:18:27Z","timestamp":1792451907578,"version":"4.5.0"},"reference-count":32,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and require life-long surveillance. Current guidelines recommend periodic whole-body MRI imaging. We assessed the incremental value of 68Ga-DOTA-octreotate (GaTate) positron emission tomography (PET)\/CT compared with conventional imaging in such patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SDHx mutation carriers who had GaTate PET\/CT were retrospectively reviewed. Detection of lesions were compared with MRI or CT on a per-patient and per-lesion basis. Proof of lesions were based on histopathology or clinical\/imaging follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty consecutive patients (median age, 46 years; 10 males) were reviewed. Fourteen patients had SDHB, four, SDHD, one SDHC, and one SDHA mutation. Fifteen had prior surgery and\/or radiotherapy. Indications for PET\/CT were as follows: 7 patients for surveillance for previously treated disease, 9 residual disease, 2 asymptomatic mutation carriers, and 2 for elevated catecholamines. Median time between modalities was 1.5 months.<\/jats:p>\n                  <jats:p>GaTate PET\/CT had higher sensitivity and specificity than conventional imaging. On a per-patient basis: PET\/CT sensitivity 100%, specificity 100%; MRI\/CT 85% and 50%. Per-lesion basis: PET\/CT sensitivity 100%, specificity 75%; MRI\/CT 80% and 25%. PET\/CT correctly identified additional small nodal and osseous lesions. MRI\/CT had more false-positive findings. Change of management resulted in 40% (8\/20 patients): 3 received localized treatment instead of observation, 1 changed to observation given extra disease detected, 4 with metastases had radionuclide therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GaTate PET\/CT provided incremental diagnostic information with consequent management impact in SDHx-pheochromocytoma and paraganglioma. Incorporating this modality as part of a surveillance program seems prudent. Further research is needed to define the optimal surveillance strategy including use of MRI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2019-00018","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:35:27Z","timestamp":1555101327000},"page":"5091-5099","source":"Crossref","is-referenced-by-count":33,"title":["The Role of 68Ga-DOTA-Octreotate PET\/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-6888","authenticated-orcid":false,"given":"Grace","family":"Kong","sequence":"first","affiliation":[{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia"},{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Schenberg","sequence":"additional","affiliation":[{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Familial Cancer Service, Peter MacCallum Cancer Centre, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Yates","sequence":"additional","affiliation":[{"name":"Endocrinology, The Royal Melbourne Hospital, Victoria, Australia"},{"name":"Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Trainer","sequence":"additional","affiliation":[{"name":"Familial Cancer Service, Peter MacCallum Cancer Centre, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirupa","family":"Sachithanandan","sequence":"additional","affiliation":[{"name":"Endocrinology, Peter MacCallum Cancer Centre, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia"},{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ravi Kumar","sequence":"additional","affiliation":[{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia"},{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Hofman","sequence":"additional","affiliation":[{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia"},{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Akhurst","sequence":"additional","affiliation":[{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia"},{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J","family":"Hicks","sequence":"additional","affiliation":[{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia"},{"name":"Neuroendocrine Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"12","key":"2019092505513801400_bib1","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"39","author":"Ta\u00efeb","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"2019092505513801400_bib2","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2019092505513801400_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/path.4503","article-title":"The genomic landscape of phaeochromocytoma","volume":"236","author":"Flynn","year":"2015","journal-title":"J Pathol"},{"issue":"2","key":"2019092505513801400_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1677\/ERC-08-0284","article-title":"Clinical aspects of SDHx-related pheochromocytoma and paraganglioma","volume":"16","author":"Timmers","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2019092505513801400_bib5","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2019092505513801400_bib6","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2019092505513801400_bib7","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2019092505513801400_bib8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction","volume":"105","author":"Jochmanov\u00e1","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2019092505513801400_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1210\/jc.2008-2419","article-title":"Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and\/or functional or nonfunctional paragangliomas","volume":"94","author":"Mannelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019092505513801400_bib10","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2019092505513801400_bib11","unstructured":"Cancer Institute NSW. Risk management for SDH-related paraganglioma-phaeochromocytoma predisposition syndromes. Available at: https:\/\/www.eviq.org.au\/cancer-genetics\/risk-management\/3558-risk-management-for-sdh-related-paraganglioma#cancer-and-tumour-risk-management-guidelines. Accessed 15 April 2019."},{"issue":"6","key":"2019092505513801400_bib12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2019092505513801400_bib13","first-page":"e68","article-title":"Von Hippel-Lindau and Hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood","volume-title":"Clin Cancer Res","author":"Rednam","year":"2017"},{"issue":"5","key":"2019092505513801400_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.beem.2013.06.004","article-title":"Determination of catecholamines in plasma and urine","volume":"27","author":"Grouzmann","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"2019092505513801400_bib15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"11","key":"2019092505513801400_bib16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"issue":"1","key":"2019092505513801400_bib17","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL","volume":"98","author":"Gimenez-Roqueplo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019092505513801400_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13053-017-0084-7","article-title":"Central nervous system gadolinium accumulation in patients undergoing periodical contrast MRI screening for hereditary tumor syndromes","volume":"16","author":"Vergauwen","year":"2018","journal-title":"Hered Cancer Clin Pract"},{"issue":"1","key":"2019092505513801400_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"(68)Ga-DOTATATE and (18)F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer Imaging"},{"issue":"4","key":"2019092505513801400_bib20","doi-asserted-by":"crossref","first-page":"T135","DOI":"10.1530\/ERC-15-0175","article-title":"15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma","volume":"22","author":"Castinetti","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2019092505513801400_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","author":"Janssen","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"2019092505513801400_bib22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2019092505513801400_bib23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","article-title":"Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases","volume":"43","author":"Archier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"2019092505513801400_bib24","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019092505513801400_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","author":"Zovato","year":"2012","journal-title":"Horm Metab Res"},{"issue":"4","key":"2019092505513801400_bib26","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"5","key":"2019092505513801400_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","author":"Pinato","year":"2016","journal-title":"Med Oncol"},{"issue":"8","key":"2019092505513801400_bib28","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00259-015-3029-2","article-title":"Peptide receptor radionuclide therapy with (90)Y\/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)","volume":"42","author":"Puranik","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2019092505513801400_bib29","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3] octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"issue":"9","key":"2019092505513801400_bib30","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019092505513801400_bib31","first-page":"500","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics","volume":"35","author":"Hofman","year":"2015"},{"issue":"11","key":"2019092505513801400_bib32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00018\/28355468\/jc.2019-00018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5091\/30051157\/jc.2019-00018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T05:53:49Z","timestamp":1569390829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/11\/5091\/5445416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00018","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,4,12]]}}}